Reductions in cardiovascular risk associated with dapagliflozin treatment in patients with type 2 diabetes are most pronounced in those who have both…
[mc4wp_form id="449"]
Treatment with EPA-DHA or vitamin D3 supplement versus placebo results in no significant difference in incident atrial fibrillation over 5 years
The post…
Diet with a high glycemic index linked to increased risk for major CV event, death for those with, without preexisting cardiovascular disease
The…
(HealthDay News) — Among heart failure patients, hospital readmission is frequent and often occurs in the early postdischarge period, according to a study published online in ESC Heart…
A 12-week treatment with empagliflozin was associated with reductions in extracellular volume, estimated plasma volume, and glomerular filtration rate (GFR) in patients with heart failure with reduced ejection…
Clinicians can enhance cardiovascular disease (CVD) risk prediction by incorporating Kidney Disease Improving Global Outcomes (KDIGO) risk categories, according to a recent study. The categories are defined by…
Elevated levels of N-terminal pro–B-type natriuretic peptide (NT-proBNP) may represent a useful biomarker for the identification of individuals at high risk for cardiovascular disease (CVD) and mortality across…
The Food and Drug Administration has expanded the approval of Entresto® (sacubitril/valsartan) in chronic heart failure to include patients with heart failure with reduced ejection fraction (HFrEF), as…
(HealthDay News) — Listening to recorded music is associated with a significant reduction in anxiety and pain following cardiac surgery, according to a review published online in Open…
(HealthDay News) — A high intake of refined grains is associated with an increased risk for mortality and major cardiovascular disease events, according to a study published online…